YHLO

2014-01-15

Summary:YHLO‘s products passed 2014 NCCL EQA (National Center for Clinical Laboratories External Quality Assessment ) , and was rewarded certificates.





YHLO‘s products passed 2014 NCCL EQA (National Center for Clinical Laboratories External Quality Assessment ) , and was rewarded certificates.

Assessment results of the following products were reported, and all these parameters were qualified for EQA. Antinuclue antibodies : ANA, RNP, Sm, SS-A, SS-B, Scl-70, Jo-1, dsDNA; Anti--cyclic citrullinated peptide antibody : CCP; Prenatal-TORCH parameters: Toxo IgG, HSV2 IgM, Toxo IgG, HSV2 IgG, CMV IgG, RV IgG, HSV1 IgM, HSV1 IgG.

Previous: “National Autoantibody EQA”

Next: CMEF Autumn 2013

Home

About YHLO

Products

Services

News

Company Profile Milestone Corporate Values

About YHLO

YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers. In May of 2021, YHLO has successfully launched IPO and listed on Shanghai Stock Exchange (Stock code: 688575).

More +

Clinical Solution CLIA ELISA LIA ESR COVID-19

Products

Based on the technology platforms of CLIA, ELISA, LIA and immunofluorescence, YHLO is specialized in diagnosis of autoimmunity, reproductive health, diabetes, infectious diseases etc.

More +